Novartis patent dispute with India sent to new appeals board

04/5/2007 | Forbes

The Novartis dispute with India over patent rights for its Glivec anti-cancer drug has been referred directly to the country's two-day-old patent appeals board. The board is to serve as the highest court determining patents in India, but Novartis notes the board's technical expert was controller general of the Indian Patent Office when it first rejected the Glivec patent last year.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA